Aktis Oncology revenue was $6.50M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2025) ending on Dec 31, 2025 was $1.9M, down N/A from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, AKTS annual revenue was $6.5M, with 336.9% growth year-over-year.
AKTS past revenue growth
How has AKTS's revenue growth performed historically?
Aktis Oncology (NASDAQ: AKTS) reported Q4 2025 revenue of $1.87 million up 100.43% year over year. In the same quarter last year, Aktis Oncology's revenue was $933.00 thousand.
What was Aktis Oncology's revenue in 2025?
Aktis Oncology's annual revenue for the twelve months ending Dec 31, 2025 was $6.50 million, a 336.92% increase year over year.
How much does Aktis Oncology make in a day?
Based on Aktis Oncology annual revenue for the past two years, AKTS makes an average of $10,936.99 per day.
What was Aktis Oncology's annual revenue growth in the past year?
As of Q2 2026, Aktis Oncology's revenue has grown 336.92% year over year. This is 128.37 percentage points lower than the US Biotechnology industry revenue growth rate of 465.29%. Aktis Oncology's revenue in the past year totaled $6.50 million.
How much does Aktis Oncology make in a year?
Aktis Oncology's revenue by year for the past two years is:
Aktis Oncology's revenue for the twelve months ending Dec 31, 2025 was $6.50 million, a 336.92% increase year over year.
Aktis Oncology's annual revenue for Dec 31, 2024 was $1.49 million, a Infinity% increase from 2023.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.